Parallel Murine and Human Aortic Wall Genomics Reveals Metabolic Reprogramming as Key Driver of Abdominal Aortic Aneurysm Progression

Background While numerous interventions effectively interfered with abdominal aortic aneurysm (AAA) formation/progression in preclinical models, none of the successes translated into clinical success. Hence, a systematic exploration of parallel and divergent processes in clinical AAA disease and its 2 primary models (the porcine pancreatic elastase and angiotensin‐II infusion [AngII] murine model) was performed to identify mechanisms relevant for aneurysm disease. Methods and Results This study combines Movat staining and pathway analysis for histological and genomic comparisons between clinical disease and its models. The impact of a notable genomic signal for metabolic reprogramming was tested in a rescue trial (AngII model) evaluating the impact of 1‐(4‐pyridinyl)‐3‐(2‐quinolinyl)‐2‐propen‐1‐one (PFK15)‐mediated interference with main glycolytic switch PFKFB3. Histological evaluation characterized the AngII model as a dissection model that is accompanied by adventitial fibrosis. The porcine pancreatic elastase model showed a transient inflammatory response and aortic dilatation, followed by stabilization and fibrosis. Normalization of the genomic responses at day 14 confirmed the self‐limiting nature of the porcine pancreatic elastase model. Clear parallel genomic responses with activated adaptive immune responses, and particularly strong signals for metabolic switching were observed in human AAA and the AngII model. Rescue intervention with the glycolysis inhibitor PFK15 in the AngII model showed that interference with the glycolytic switching quenches aneurysm formation. Conclusions Despite clear morphological contrasts, remarkable genomic parallels exist for clinical AAA disease and the AngII model. The metabolic response appears causatively involved in AAA progression and provides a novel therapeutic target. The clear transient genomic response classifies the porcine pancreatic elastase model as a disease initiation model.

[1]  B. Modarai,et al.  Top 10 candidate aortic disease trials , 2020, Journal of internal medicine.

[2]  J. Spin,et al.  Long noncoding RNAs in key cellular processes involved in aortic aneurysms , 2019, Atherosclerosis.

[3]  Fei-Fei Liu,et al.  Targeting metabolic dysregulation for fibrosis therapy , 2019, Nature Reviews Drug Discovery.

[4]  Jing Wang,et al.  Metformin prescription and aortic aneurysm: systematic review and meta-analysis , 2019, Heart.

[5]  J. Matsumura,et al.  Pharmacologic Management of Aneurysms. , 2019, Circulation research.

[6]  Gregory T. Jones,et al.  Genetics of Thoracic and Abdominal Aortic Diseases. , 2019, Circulation research.

[7]  P. Kolh,et al.  Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. , 2019, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[8]  P. Tsao,et al.  H19 Induces Abdominal Aortic Aneurysm Development and Progression , 2018, Circulation.

[9]  E. Abraham,et al.  Metformin reverses established lung fibrosis in a bleomycin model , 2018, Nature Medicine.

[10]  A. Benigni,et al.  Sirtuins in Renal Health and Disease. , 2018, Journal of the American Society of Nephrology : JASN.

[11]  Yan Wang,et al.  Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease. , 2017, Journal of vascular surgery.

[12]  L. Holdt,et al.  Molecular Fingerprint for Terminal Abdominal Aortic Aneurysm Disease , 2017, Journal of the American Heart Association.

[13]  T. Lehtimäki,et al.  Differentially expressed genes and canonical pathways in the ascending thoracic aortic aneurysm – The Tampere Vascular Study , 2017, Scientific Reports.

[14]  M. Stampanoni,et al.  Angiotensin II infusion into ApoE-/- mice: a model for aortic dissection rather than abdominal aortic aneurysm? , 2017, Cardiovascular research.

[15]  J. Golledge,et al.  A systematic review investigating the association of microRNAs with human abdominal aortic aneurysms. , 2017, Atherosclerosis.

[16]  R. Stolker,et al.  Risk of abdominal aortic aneurysm (AAA) among male and female relatives of AAA patients , 2017, Vascular medicine.

[17]  L. Joosten,et al.  Cellular metabolism of myeloid cells in sepsis , 2017, Journal of leukocyte biology.

[18]  R. Coscas,et al.  Translational Relevance and Recent Advances of Animal Models of Abdominal Aortic Aneurysm. , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[19]  S. Ergün,et al.  Extra- and Intraluminal Elastase Induce Morphologically Distinct Abdominal Aortic Aneurysms in Mice and Thus Represent Specific Subtypes of Human Disease , 2016, Journal of Vascular Research.

[20]  Alexey Sergushichev,et al.  An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation , 2016 .

[21]  W. Mali,et al.  18F-FDG PET scanning of abdominal aortic aneurysms and correlation with molecular characteristics: a systematic review , 2015, EJNMMI Research.

[22]  Gang Liu,et al.  Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. , 2015, American journal of respiratory and critical care medicine.

[23]  J. Lindeman.  The pathophysiologic basis of abdominal aortic aneurysm progression: a critical appraisal , 2015, Expert review of cardiovascular therapy.

[24]  C. Pilarsky,et al.  Differential gene expression in human abdominal aortic aneurysm and aortic occlusive disease , 2015, Oncotarget.

[25]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[26]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[27]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[28]  P. Tsao,et al.  miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development , 2014, Nature Communications.

[29]  R. Virmani,et al.  Clinical classification of plaque morphology in coronary disease , 2014, Nature Reviews Cardiology.

[30]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[31]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[32]  F. Lederle.  Abdominal Aortic Aneurysm: Still No Pill , 2013, Annals of Internal Medicine.

[33]  Chih-Hao Chang,et al.  Fueling Immunity: Insights into Metabolism and Lymphocyte Function , 2013, Science.

[34]  V. de Waard,et al.  Immunosuppressive Drug Azathioprine Reduces Aneurysm Progression Through Inhibition of Rac1 and c-Jun-Terminal-N-Kinase in Endothelial Cells , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[35]  J. Trent,et al.  Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer , 2013, Molecular Cancer Therapeutics.

[36]  T. Miyakawa,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .

[37]  B. Schehler,et al.  Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity , 2012, Experimental and Clinical Endocrinology & Diabetes (Barth).

[38]  C. Bhamidipati,et al.  Development of a novel murine model of aortic aneurysms using peri-adventitial elastase. , 2012, Surgery.

[39]  S. Nagamachi,et al.  Inhibition of Development of Abdominal Aortic Aneurysm by Glycolysis Restriction , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[40]  Daniel Rico,et al.  Substrate Fate in Activated Macrophages: A Comparison between Innate, Classic, and Alternative Activation , 2010, The Journal of Immunology.

[41]  R. Bank,et al.  Distinct defects in collagen microarchitecture underlie vessel-wall failure in advanced abdominal aneurysms and aneurysms in Marfan syndrome , 2009, Proceedings of the National Academy of Sciences.

[42]  Peter F. Stadler,et al.  Fast Mapping of Short Sequences with Mismatches, Insertions and Deletions Using Index Structures , 2009, PLoS Comput. Biol..

[43]  P. Tsao,et al.  Creation of murine experimental abdominal aortic aneurysms with elastase. , 2009, Journal of visualized experiments : JoVE.

[44]  J. Golledge,et al.  Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm , 2009, BMC Genomics.

[45]  J. H. van Bockel,et al.  Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm. , 2008, Clinical science.

[46]  B. Baxter,et al.  Medical management of small abdominal aortic aneurysms. , 2008, Circulation.

[47]  M. Pfaffl.  Relative quantification , 2006 .

[48]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Egger,et al.  Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. , 2004, European journal of public health.

[50]  A. Matsukawa,et al.  INNATE IMMUNE RESPONSE IN TH1- AND TH2-DOMINANT MOUSE STRAINS , 2004, Shock.

[51]  D. Vertommen,et al.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. , 2004, The Biochemical journal.

[52]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[53]  A. Daugherty,et al.  Aortic Dissection Precedes Formation of Aneurysms and Atherosclerosis in Angiotensin II-Infused, Apolipoprotein E-Deficient Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[54]  B. Høivik,et al.  [Abdominal aortic aneurysms]. , 1994, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[55]  A. Glazko.  EFFECT OF BLOOD PROTEASE AND TRYPSIN INHIBITOR ON THE CLOTTING MECHANISM. , 1947, The Journal of clinical investigation.